What does early evidence say about cannabis for autism spectrum disorder?

A review of preclinical and clinical data found potential therapeutic benefit for cannabis and CBD in autism spectrum disorder, with authors adding their own clinical experience treating children and young adults.

Mostafavi, Mojdeh et al.·Seminars in pediatric neurology·2020·Preliminary EvidenceReview
RTHC-02732ReviewPreliminary Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

The review found emerging preclinical evidence linking the endocannabinoid system to ASD pathophysiology and limited clinical data suggesting cannabis and CBD may improve core symptoms (social interaction, communication), noncore behaviors (aggression, self-injury), and comorbidities. The authors clinical experience supported these findings, noting overall tolerability.

Key Numbers

No effective treatment for ASD core symptoms currently exists; limited clinical data from small studies and case series reviewed.

How They Did This

Narrative review of preclinical and clinical data on cannabis/CBD for ASD core symptoms, noncore symptoms, and comorbidities, supplemented by authors clinical experience with ASD patients using cannabis.

Why This Research Matters

No effective treatment exists for ASD core symptoms. Cannabis and CBD represent one of the few emerging therapeutic options, but evidence remains very early-stage, making careful clinical reviews particularly valuable.

The Bigger Picture

The endocannabinoid system is involved in social behavior, emotion regulation, and neuroplasticity, all relevant to ASD. While the biological rationale is plausible, the evidence has not yet caught up to parental demand for cannabis-based treatments.

What This Study Doesn't Tell Us

Very limited clinical data; no large RCTs; narrative review format; clinical experience is anecdotal; ASD heterogeneity makes generalizing difficult; long-term safety in developing brains unknown.

Questions This Raises

  • ?Would different CBD-to-THC ratios work better for different ASD symptoms?
  • ?Can we identify which ASD subgroups respond best to cannabinoid treatment?

Trust & Context

Key Stat:
No effective treatment exists for ASD core symptoms; cannabis shows early promise
Evidence Grade:
Preliminary: limited clinical data, no large RCTs, supplemented by anecdotal clinical experience.
Study Age:
Published 2020.
Original Title:
Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience.
Published In:
Seminars in pediatric neurology, 35, 100833 (2020)
Database ID:
RTHC-02732

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Does cannabis help autism?

Early preclinical and clinical data suggest potential benefit for both core symptoms and associated behaviors. However, the evidence is very limited and no large controlled trials have been completed.

Is cannabis safe for children with autism?

The review found cannabis and CBD were generally well tolerated in clinical experience, but long-term safety data in developing brains are lacking. This remains an active area of research.

Read More on RethinkTHC

Cite This Study

RTHC-02732·https://rethinkthc.com/research/RTHC-02732

APA

Mostafavi, Mojdeh; Gaitanis, John. (2020). Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience.. Seminars in pediatric neurology, 35, 100833. https://doi.org/10.1016/j.spen.2020.100833

MLA

Mostafavi, Mojdeh, et al. "Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience.." Seminars in pediatric neurology, 2020. https://doi.org/10.1016/j.spen.2020.100833

RethinkTHC

RethinkTHC Research Database. "Autism Spectrum Disorder and Medical Cannabis: Review and Cl..." RTHC-02732. Retrieved from https://rethinkthc.com/research/mostafavi-2020-autism-spectrum-disorder-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.